Choriogonadotropin alfa biosimilar - Dong-A ST

Drug Profile

Choriogonadotropin alfa biosimilar - Dong-A ST

Alternative Names: DA 3803; r-hCG

Latest Information Update: 08 Oct 2015

Price : $50

At a glance

  • Originator Dong-A Pharmaceutical
  • Developer Dong-A ST
  • Class Gonadotropins; Infertility therapies; Peptide hormones; Pituitary gonadotropins; Placental hormones; Recombinant proteins
  • Mechanism of Action Ovarian follicle stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Female infertility

Highest Development Phases

  • Preregistration Female infertility

Most Recent Events

  • 26 May 2015 Choriogonadotropin alfa biosimilar - Dong-A ST is available for licensing in World as of 26 May 2015. http://en.donga-st.com
  • 26 May 2015 Dong A announces intention to submit NDA to KFDA (Dong-A ST 1Q report, May 2015)
  • 19 Jan 2015 Choriogonadotropin alfa biosimilar is still in phase III development for Female infertility in South Korea
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top